Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Molecular Cytogenetics Market Set to Reach USD 1.43 Billion by 2030 | MarketsandMarkets™

globenewswire.com
TMO Mentioned as a product manufacturer in the molecular cytogenetics value chain, indicating its role in the growing market. ABT Listed as a product manufacturer within the molecular cytogenetics market value chain, suggesting its involvement in the sector's growth. ILMN Identified as a prominent market participant in the molecular cytogenetics sector, implying its contribution to the market's expansion. DHR Named as a prominent market participant in the molecular cytogenetics industry, indicating its presence and potential role in market growth. AGNC Mentioned as a prominent market participant in the molecular cytogenetics industry, suggesting its role in the sector's growth. PACB Included as a prominent market participant in the molecular cytogenetics space, indicating its engagement in the expanding market. BIO DGX Identified as a service provider in the molecular cytogenetics value chain, suggesting its role in the growing market. PFE Mentioned as an end user (pharmaceutical leader) in the molecular cytogenetics ecosystem, indicating its interest in the technology. AZN Listed as a pharmaceutical leader and end user in the molecular cytogenetics value chain, indicating its engagement with the technology.

Delray Beach, FL, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Emerging markets, breakthrough technologies, and strategic M&A reshape competitive landscape

The global molecular cytogenetics market is projected to reach USD 1.43 billion by 2030 from USD 1.02 billion in 2025 at a CAGR of 7.1% from 2025 to 2030. The surge is attributed to rapidly increasing global cancer rates, growing genetic disorder prevalence, and the expanding adoption of advanced cytogenetic technologies in clinical pathology testing.

Why this matters now

As healthcare systems worldwide accelerate toward precision medicine, the ability to detect chromosomal abnormalities and genomic variations is becoming essential for oncology and genetic diagnostics. For hospital networks, research centers, pharmaceutical companies, and CROs, molecular cytogenetics is enabling faster treatment decisions, improved patient outcomes, and streamlined laboratory workflows.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224

Market Dynamics: Drivers, Restraints, Opportunities & Challenges

What is driving growth?

The rising incidence of cancer and genetic disorders is significantly increasing demand for high-resolution cytogenetic testing solutions, enabling accurate diagnosis, prognosis, and personalized therapy planning.

What is slowing adoption?

High costs associated with advanced instruments and reagents continue to restrict accessibility for smaller laboratories and emerging regions, delaying large-scale deployment.

Where are the growth opportunities?

Untapped emerging markets across Asia Pacific and Latin America offer substantial expansion potential, fueled by increased healthcare investments, infrastructure development, and rising genomic testing awareness.

What challenges remain?

The industry is transitioning from traditional FISH methods to array-based techniques, requiring workflow upgrades, specialized training, and system integration — all of which may temporarily slow market adoption.

Market Landscape & Ecosystem Collaboration

The molecular cytogenetics value chain includes raw material suppliers such as New England Biolabs and Merck KGaA; product manufacturers including Thermo Fisher Scientific and Abbott; service providers such as Quest Diagnostics and Reliance Life Sciences; global regulatory agencies including the US FDA and the European Medicines Agency; and end users spanning pharmaceutical leaders like Pfizer and AstraZeneca.

Collaboration across this ecosystem is essential for innovation, scalability, and validated clinical performance.

Segment Insights

By Product & Service

In 2024, kits & reagents dominated the market, driven by demand for standardized, ready-to-use solutions that ensure accuracy, reproducibility, and regulatory compliance.

By Technique

Comparative Genomic Hybridization (CGH) led the market due to superior detection of genome-wide chromosomal abnormalities compared with legacy cytogenetic methods.

By Application

Cancer applications accounted for the largest market share in 2024, supported by the global shift toward precision oncology and targeted therapy selection.

Regional Outlook

Asia Pacific is projected to post the highest CAGR through 2030, propelled by expanding precision medicine initiatives, growing diagnostic infrastructure, and an increasing patient population.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=148469224

Competitive Landscape

The market is consolidated, with leading companies controlling 42–47% of total share.

F. Hoffmann-La Roche Ltd. maintains a dominant position through an extensive portfolio across instruments, diagnostic kits, software platforms, and services. BioView (Israel) is emerging rapidly as an innovator in automated imaging and analysis solutions.

Prominent market participants include:

Thermo Fisher Scientific, Illumina, Danaher, Roche, Revvity, Abbott, Agilent Technologies, PacBio, Bio-Rad Laboratories, Bio-Techne, GeneDx, Insight Molecular Diagnostics, BioView, Applied Spectral Imaging, CytoTest, KromaTiD, Biomodal, and BioCare Medical.

Strategic Developments & Technology Milestones

Leadership Spotlight

For more information, Inquire Now!

Discover Connected Healthcare Market Opportunities:

Genomics Market

Next Generation Sequencing Market

Cancer Biomarkers Market

Gene Therapy Market

In Vitro Diagnostics Market

Get access to the latest updates on Top Companies in Molecular Cytogenetics and Molecular Cytogenetics Market Size